BioNTech (BNTX) to Release Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) is projected to release its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect BioNTech to post earnings of ($0.57) per share and revenue of $941.9940 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

BioNTech Trading Down 0.4%

NASDAQ:BNTX opened at $101.50 on Friday. BioNTech has a 1 year low of $81.20 and a 1 year high of $124.00. The stock’s fifty day moving average price is $106.82 and its two-hundred day moving average price is $103.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The company has a market cap of $22.86 billion, a P/E ratio of -38.59 and a beta of 1.51.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BNTX. UBS Group upgraded BioNTech to a “hold” rating in a research note on Thursday, December 4th. Leerink Partners lowered BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a report on Friday, January 23rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a research report on Wednesday, December 3rd. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $140.10.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently bought and sold shares of BNTX. Royal Bank of Canada raised its position in shares of BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after buying an additional 3,514 shares in the last quarter. NewEdge Advisors LLC purchased a new position in BioNTech in the first quarter worth $167,000. Russell Investments Group Ltd. increased its stake in BioNTech by 368,800.0% in the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after acquiring an additional 11,064 shares during the last quarter. Natixis bought a new stake in BioNTech during the second quarter worth about $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after purchasing an additional 13,788 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.